← Back to patent-cliff list
Olmesartan Medoxomil/Azelnidipine
Tier C — Watch / tradeOlmesartan Medoxomil/Azelnidipine
Daiichi Sankyo Co., Ltd.
Originator
2010
First approval
-
Expiry (public)
$0.15B ▲
Peak sales
Small molecule
Type
Targets：AT1, Voltage-gated L-type calcium channel
Brand：Rezaltas
Indications (approved)：Hypertension
Regional status
US
-
EU
-
China
-
Japan
Approved
2010-01-20
Factories producing this API11
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
11 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates6 routes
Originator routes × 2Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 7 · Total yield 16.6 g
OLME-0011187-42-4OLME-00243083-12-1OLME-00351802-42-7OLME-004144689-94-1OLME-005144689-93-0OLME-006124750-51-2OLME-007144690-33-5OLME-0081114761-92-0OLME-00980841-78-7OLME-010144690-92-6API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| OLME-001 | 1187-42-4 | (2R,3R,4R,5S)-2-((benzoyloxy)methyl)-5-bromotetrahydrofuran-3,4-diyl dibenzoate |
| OLME-002 | 43083-12-1 | 1,1,1-trimethoxybutane |
| OLME-003 | 51802-42-7 | 2-propyl-1H-imidazole-4,5-dicarbonitrile |
| OLME-004 | 144689-94-1 | diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate |
| OLME-005 | 144689-93-0 | ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-006 | 124750-51-2 | 5-(4'-(bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole |
| OLME-007 | 144690-33-5 | ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate |
| OLME-008 | 1114761-92-0 | lithium 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate |
| OLME-009 | 80841-78-7 | 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one |
| OLME-010 | 144690-92-6 | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate |
OriginatorRoute 1Steps 4 · Total yield 2.17 g
AZEL-00191-00-9AZEL-002106-89-8AZEL-00318621-17-5AZEL-004372-09-8AZEL-005116574-14-2AZEL-006170749-59-4AZEL-007—API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| AZEL-001 | 91-00-9 | diphenylmethanamine |
| AZEL-002 | 106-89-8 | 2-(chloromethyl)oxirane |
| AZEL-003 | 18621-17-5Available | 1-benzhydrylazetidin-3-ol |
| AZEL-004 | 372-09-8Available | 2-cyanoacetic acid |
| AZEL-005 | 116574-14-2 | 1-benzhydrylazetidin-3-yl 2-cyanoacetate |
| AZEL-006 | 170749-59-4 | 1-benzhydrylazetidin-3-yl 3-amino-3-iminopropanoate acetate |
| AZEL-007 | - | isopropyl (E)-2-(3-nitrobenzylidene)-3-oxobutanoate |
OptimisedRoute 2Steps 5 · Total yield /
OLME-004144689-94-1OLME-005144689-93-0OLME-00980841-78-7OLME-010144690-92-6OLME-011114772-54-2OLME-012144690-96-0OLME-013144689-24-7API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| OLME-004 | 144689-94-1 | diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate |
| OLME-005 | 144689-93-0 | ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-009 | 80841-78-7 | 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one |
| OLME-010 | 144690-92-6 | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate |
| OLME-011 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| OLME-012 | 144690-96-0 | ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-013 | 144689-24-7 | 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid |
OptimisedRoute 3Steps 3 · Total yield /
OLME-005144689-93-0OLME-006124750-51-2OLME-00980841-78-7OLME-010144690-92-6OLME-014144690-04-0OLME-015—API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| OLME-005 | 144689-93-0 | ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-006 | 124750-51-2 | 5-(4'-(bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole |
| OLME-009 | 80841-78-7 | 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one |
| OLME-010 | 144690-92-6 | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate |
| OLME-014 | 144690-04-0 | 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid |
| OLME-015 | - | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
OptimisedRoute 4Steps 5 · Total yield 40 mg
OLME-005144689-93-0OLME-00980841-78-7OLME-016589-15-1OLME-017685091-51-4OLME-018—OLME-019—OLME-020—OLME-021—API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| OLME-005 | 144689-93-0 | ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-009 | 80841-78-7 | 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one |
| OLME-016 | 589-15-1 | 1-bromo-4-(bromomethyl)benzene |
| OLME-017 | 685091-51-4 | ethyl 1-(4-bromobenzyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-018 | - | (2-(1-(2-phenylpropan-2-yl)-1H-tetrazol-5-yl)phenyl)boronic acid |
| OLME-019 | - | ethyl 4-(2-hydroxypropan-2-yl)-1-((2'-(1-(2-phenylpropan-2-yl)-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-propyl-1H-imidazole-5-carboxylate |
| OLME-020 | - | 4-(2-hydroxypropan-2-yl)-1-((2'-(1-(2-phenylpropan-2-yl)-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-propyl-1H-imidazole-5-carboxylic acid |
| OLME-021 | - | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-1-((2'-(1-(2-phenylpropan-2-yl)-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-propyl-1H-imidazole-5-carboxylate |
OptimisedRoute 5Steps 5 · Total yield /
OLME-00980841-78-7OLME-011114772-54-2OLME-022—OLME-023—OLME-0241309566-95-7OLME-0251199807-52-7OLME-0261993494-83-9API · Olmesartan Medoxomil/Azelnidipine
| Code | CAS No. | Intermediate |
|---|---|---|
| OLME-009 | 80841-78-7 | 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one |
| OLME-011 | 114772-54-2 | 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile |
| OLME-022 | - | 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carbonitrile |
| OLME-023 | - | 4,4-dimethyl-2-propyl-4,6-dihydro-1H-furo[3,4-d]imidazol-6-ol |
| OLME-024 | 1309566-95-7 | 4'-((6-hydroxy-4,4-dimethyl-2-propyl-4,6-dihydro-1H-furo[3,4-d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile |
| OLME-025 | 1199807-52-7 | 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid |
| OLME-026 | 1993494-83-9 | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
Frequently asked questions
What are the approved indications of Olmesartan Medoxomil/Azelnidipine?
Approved indications include: Hypertension.
When does the Olmesartan Medoxomil/Azelnidipine patent expire?
No public expiry year is available for Olmesartan Medoxomil/Azelnidipine yet; this page updates once verified.
How many synthesis routes are recorded for Olmesartan Medoxomil/Azelnidipine?
6 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Olmesartan Medoxomil/Azelnidipine intermediates?
2 intermediate CAS of Olmesartan Medoxomil/Azelnidipine are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Olmesartan Medoxomil/Azelnidipine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29